Dishonesty in medicine revisited

Texas Heart Institute Journal

Volumn 35, Issue 1, 2008, Pages 6-15

  Fred, Herbert L ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

EDITORIAL; HEALTH CARE DELIVERY; HONESTY; HUMAN; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICAL SCHOOL; PATIENT CARE; PROFESSIONAL MISCONDUCT;

FRAUD; HUMANS; PHYSICIANS; PROFESSIONAL MISCONDUCT; STUDENTS, MEDICAL;

EID: 42549146068     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Editorial

References (85)

1. Wenzel RP, Edmond MB. Team-based prevention of catheter-related infections. N Engl J Med 2006;355(26):2781-3.
2. Zuger A. Dissatisfaction with medical practice. N Engl J Med 2004;350(1):69-75.
3. Fred HL. On the sagging of medical professionalism. Texas Medical Board Bulletin 2004;2(1):1,3.
4. Fred HL. Hyposkillia: deficiency of clinical skills. Tex Heart Inst J 2005;32(3):255-7.
5. Feddock CA. The lost art of clinical skills. Am J Med 2007;120(4):374-8.
6. Fred HL. Dishonesty in medicine. South Med J 1984;77(10):1221-2.
7. Sierles F, Hendrickx I, Circle S. Cheating in medical school. J Med Educ 1980;55(2):124-5.
8. Harper MG. High tech cheating. Nurse Educ Today 2006;26(8):672-9.
9. Stimmel B. Cheating in medical school: a problem or an annoyance? R I Med J 1990;73(9):413-6.
10. Simpson DE, Yindra KJ, Towne JB, Rosenfeld PS. Medical students' perceptions of cheating. Acad Med 1989;64(4):221-2.
11. Fuller JL, Killip DE. Do dental students cheat? J Dent Educ 1979;43(13):666-70.
12. Brown DL. Cheating must be okay - everybody does it! Nurse Educ 2002;27(1):6-8.
13. Young TA. Teaching medical students to lie. The disturbing contradiction: medical ideals and the resident-selection process. CMAJ 1997;156(2):219-22.
14. Teherani A, Hodgson CS, Banach M, Papadakis MA. Domains of unprofessional behavior during medical school associated with future disciplinary action by a state medical board. Acad Med 2005;80(10 Suppl):S17-20.
15. Papadakis MA, Hodgson CS, Teherani A, Kohatsu ND. Unprofessional behavior in medical school is associated with subsequent disciplinary action by a state medical board. Acad Med 2004;79(3):244-9.
16. Papadakis MA, Teherani A, Banach MA, Knettler TR, Rattner SL, Stern DT, et al. Disciplinary action by medical boards and prior behavior in medical school. N Engl J Med 2005;353 (25):2673-82.
17. Silver HK, Glicken AD. Medical student abuse. Incidence, severity, and significance. JAMA 1990;263(4):527-32.
18. Sheehan KH, Sheehan DV, White K, Leibowitz A, Baldwin DC Jr. A pilot study of medical student 'abuse'. Student perceptions of mistreatment and misconduct in medical school. JAMA 1990;263(4):533-7.
19. Friedman RB. Sounding board. Fantasy land. N Engl J Med 1983;308(11):651-3.
20. Fred HL. The blind leading the blind. Hosp Pract (Minneap) 2000;35(5):12,14-5.
21. Levin LA. The perils of PERRLA. Ann Intern Med 2007;146(8):615-6.
22. Morgenstern L. A piece of my mind. Will the real doctor please stand up? JAMA 2003;289(1):18.
23. Fred HL. Passing the buck. South Med J 1982;75(10):1164-5.
24. Appleby J. Medical claims 'mined' to find fraud. Use of detection software spreads. USA Today 2006 Nov 7;Sect. B:1.
25. Goldwyn RM. Reporting or hiding a complication. Plast Reconstr Surg 1983;71(6):843-4.
26. Brent RL. The irresponsible expert witness: a failure of biomedical graduate education and professional accountability. Pediatrics 1982;70(5):754-62.
27. Wilmshurst P. Doctors seem not to be punished for dishonesty in their cv. BMJ 2001;323(7324):1309.
28. Abelson R. Some hospitals call 911 to save their patients. New York Times 2007 Apr 2 [cited 2007 Oct 16]. Available from: http://www.nytimes.com/2007/04/ 02/business/02alarm.html.
29. Nallamothu BK, Rogers MA, Chernew ME, Krumholz HM, Eagle KA, Birkmeyer JD. Opening of specialty cardiac hospitals and use of coronary revascularization in Medicare beneficiaries. JAMA 2007;297(9):962-8.
30. Tonelli MR. Conflict of interest in clinical practice. Chest 2007;132(2):664-70.
31. Saul S. New prostate treatment has strong profit motive. Houston Chronicle 2006 Dec 10;Sect. A:27.
32. Kassirer JP. On the take: How medicine's complicity with big business can endanger your health. Oxford (UK): Oxford University Press; 2005.
33. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287(5):612-7.
34. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007;356(17):1742-50.
35. Campbell EG. Doctors and drug companies - scrutinizing influential relationships. N Engl J Med 2007;357(18):1796-7.
36. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, Rennie D. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998;280(3):222-4.
37. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, et al. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 2002;287(21):2769-71.
38. Pignatelli B, Maisonneuve H, Chapuis F. Authorship ignorance: views of researchers in French clinical settings. J Med Ethics 2005;31(10):578-81.
39. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;4(1):e19 [cited 2007 Oct 16]. Available from: http://medicine.plosjournals.org/perlserv/ ?request=get-document& doi= 10.1371/journal.pmed.0040019&ct=1.
40. Woolley KL. Goodbye ghostwriters! How to work ethically and efficiently with professional medical writers. Chest 2006; 130(3):921-3.
41. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283(3):373-80.
42. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth 2003;3(3):39-46.
43. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992;102(1):270-3.
44. Harris G, Roberts J. Doctors' ties to drug makers are put on close view. New York Times 2007 Mar 21 [cited 2007 Oct 16]. Available from: http://www.ny times.com/2007/03/21/us/21drug.html.
45. Carlat D. Overdose: Industry teaches our doctors. Houston Chronicle 2007 June 17;Sect. E:1,4.
46. Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med 2002;346(24):1901-2.
47. Kahn JM, Goitein L, Ouellette DR, Irwin RS. Pharmaceutical industry sponsorship of journal supplements. Chest 2006;129(5):1387; author reply 1387-8.
48. Ryan KJ. Research misconduct in clinical research - the American experience and response. Acta Oncol 1999;38(1):93-7.
49. Culliton BJ. Coping with fraud: the Darsee Case. Science 1983;220(4592):31-5.
50. Relman AS. Lessons from the Darsee affair. N Engl J Med 1983;308(23):1415-7.
51. Knox R. The Harvard fraud case: where does the problem lie? JAMA 1983;249(14):1797-9,1802-7.
52. Hwang WS, Ryu YJ, Park JH, Park ES, Lee EG, Koo JM, et al. Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst [published erratum appears in Science 2005;310(5755):1769; published retraction appears in Kennedy D. Science 2006;311(5759):335]. Science 2004;303(5664):1669- 74.
53. Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, et al. Patient-specific embryonic stem cells derived from human SCNT blastocysts [published erratum appears in Science 2005;310(5755):1769; published retraction appears in Kennedy D. Science 2006;311(5759):335]. Science 2005;308 (5729):1777-83.
54. Kennedy D. Editorial retraction [Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, et al. Science 2005;308 (5729):1777-83
55. and Hwang WS, Ryu YJ, Park JH, Park ES, Lee EG, Koo JM, et al. Science 2004;303(5664):1669-74].
56. Science 2006;311(5759):335.
57. Prosecutors charge disgraced cloning scientist. Guardian (UK) 2006 May 12 [cited 2007 Oct 16]. Available from: http://www.guardian.co.uk/science/2006/ may/12/stemcells.genetics.
58. Assael LA. Lies: the cruelty of scientific and clinical dishonesty. J Oral Maxillofac Surg 2006;64(4):569-70.
59. Sox HC, Rennie D. Research misconduct, retraction, and cleansing the medical literature: lessons from the Poehlman case. Ann Intern Med 2006;144(8):609-13.
60. Laine C, Goodman SN, Griswold ME, Sox HC. Reproducible research: moving toward research the public can really trust. Ann Intern Med 2007;146(6):450-3.
61. Frizelle F. Research dishonesty and conflict of interest. N Z Med J 2002;115(1167) [cited 2007 Oct 16]. Available from: http://www.nzma.org.nz/ journal/115-1167/270/.
62. Wilmshurst P. Institutional corruption in medicine [published erratum appears in BMJ 2003;326(7384):333]. BMJ 2002;325(7374):1232-5.
63. Angell M. The truth about the drug companies. How they deceive us and what to do about it. New York: Random House; 2005.
64. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338(2):101-6.
65. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289(4):454-65.
66. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163(2):185-94.
67. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326(7400):1171-3.
68. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358(3): 252-60.
69. Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007;109(7):1239-46.
70. Kelly RE Jr, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 2006; 36(11):1647-56.
71. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 2006;333(7572):782.
72. Manwell C, Baker CM. Honesty in science: a partial test of a sociobiological model of the social structure of science. Search 1981;12(6):151-60.
73. Ingelfinger FJ. Peer review in biomedical publication. Am J Med 1974;56(5):686-92.
74. Special Correspondent. Must plagiarism thrive? Br Med J 1980;281(6232):41-2.
75. Cicutto L. Plagiarism: avoiding the peril in scientific writing. Chest 2008;133(2):579-81.
76. Vaisrub S. Autoplagiarism. JAMA 1978;239(5):437.
77. Lock S. Peer review weighed in the balance. Br Med J (Clin Res Ed) 1982;285(6350):1224-6.
78. Wade N. It may look authentic; here's how to tell it isn't. New York Times 2006 Jan 24 [cited 2007 Oct 16]. Available from: http://www.nytimes.com/ 2006/01/24/science/24frau.html.
79. Flynn K. Controversy continues about contributions of medical writers. AMWA J 2006;21(2):56-7.
80. Mathews AW. Ghost story. At medical journals, writers paid by industry play big role [reprinted with permission from Wall Street Journal 2005 Dec 13]. AMWA J 2006;21(1):2-4.
81. Eaton L. Medical editors issue guidance on ghost writing. BMJ 2005;330(7498):988.
82. Hargreaves S. Ghost authorship of industry funded drug trials is common, say researchers. BMJ 2007;334(7587):223.
83. Smith R. Editorial misconduct. BMJ 2003;326(7401):1224-5.
84. Saul S. Doctor accused of leak to drug maker [article on the Internet]. New York: The New York Times 2008 Jan 31 [cited 2008 Jan 31]. Available from: http://www.nytimes.com/2008/01/31/business/31censure.html?_r=1&ref= business&oref= slogin.
85. Vastag B. Reviewer leaked Avandia study to drug firm. Nature 2008;451:509.